Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
McKesson
Boehringer Ingelheim
McKinsey
Argus Health
Cantor Fitzgerald

Generated: May 27, 2019

DrugPatentWatch Database Preview

Adalimumab - Biologic Drug Details

« Back to Dashboard

Summary for adalimumab
Tradenames:1
Patents:384
Applicants:1
BLAs:1
Suppliers: see list2
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for adalimumab
Pharmacology for adalimumab

US Patents for adalimumab

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Try a Free Trial Massachusetts Eye and Ear Infirmary (Boston, MA) ➤ Try a Free Trial RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Try a Free Trial UNIVERSITY OF TROMSO (Tromso, NO) ➤ Try a Free Trial RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Try a Free Trial SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) ➤ Try a Free Trial RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Try a Free Trial AMGEN INC. (Thousand Oaks, CA) ➤ Try a Free Trial RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Try a Free Trial Knopp Biosciences LLC (Pittsburgh, PA) ➤ Try a Free Trial RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Try a Free Trial Coherus Biosciences, Inc. (Redwood City, CA) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for adalimumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016 00056 Denmark ➤ Try a Free Trial PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2016)3293 20160530
2017 00012 Denmark ➤ Try a Free Trial PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707
2016 00031 Denmark ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
2015000061 Germany ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
2015017,C2201840 Lithuania ➤ Try a Free Trial PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 20141021
2016 00031 Denmark ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Healthtrust
Argus Health
US Department of Justice
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.